LPPEPTIDE | Cagrilintide 10mg | 10mg x 10 vials | 10 vials / box

What is CGL10?

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile

Research context

Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing

Reference literature focus

Cagrilintide is dosed at 600 mcg–4.5 mg weekly by subcutaneous injection in educational protocols, starting low and titrating upward. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

LPPeptide handling reference

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration. Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks). Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 0.0333 mg (33.3 mcg) on a U‑100 insulin syringe. Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Preparation

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming or vigorous agitation. Gently swirl or roll until fully dissolved (do not shake). Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.

Storage

Proper storage preserves peptide integrity and potency. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles. Allow vials to reach room temperature before opening to reduce condensation uptake

Safety observations

Complementary strategies for optimal outcomes. Pair with a balanced, protein‑forward diet tailored to individual energy needs. Combine resistance training and aerobic activity to support metabolic health and preserve lean mass. Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery. Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects

Contraindications

Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo. Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone. Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg). Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient. Gradual titration helps minimize these effects. Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites